For fiscal 2025 (ended Dec 31, 2025), Cellectis S.A. reported $79.59M of revenue and -$67.59M of net income.
CLLS revenue was $79.59M for fiscal 2025 (ended Dec 31, 2025), up 61.7% from fiscal 2024. Compound annual growth was +6.0% over 5 years and +2.4% over 10 years. It rose in 4 of the last 10 fiscal years. Fiscal 2025 is the highest of the 12 fiscal years on file.
CLLS net income was -$67.59M for fiscal 2025 (ended Dec 31, 2025), compared with -$36.76M in fiscal 2024.
CLLS diluted EPS was -$0.67 for fiscal 2025 (ended Dec 31, 2025), compared with -$0.41 in fiscal 2024.
CLLS free cash flow was -$41.76M for fiscal 2025 (ended Dec 31, 2025), compared with $20.41M in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $79.59M | $49.22M | $9.19M | $25.73M | $38.60M | $59.56M | $22.99M | $21.43M | $33.72M | $56.44M |
| Cost of revenue | $0 | $0 | $737.0K | $1.77M | $1.84M | $1.95M | $11.39M | $2.74M | $2.62M | - |
| Gross profit | $79.59M | $49.22M | $8.46M | $23.95M | $36.75M | $57.61M | $11.60M | $18.69M | $31.09M | - |
| Research and development | $93.52M | $90.54M | $87.65M | $97.50M | $117.84M | $77.05M | $92.04M | $76.57M | $79.23M | $78.46M |
| Selling, general and admin | $19.79M | $19.09M | $16.81M | $17.49M | $22.88M | $22.51M | $43.02M | $47.25M | $44.75M | $43.41M |
| Operating income | -$33.08M | -$59.55M | -$97.30M | -$89.67M | -$103.48M | -$42.31M | -$123.55M | -$105.09M | -$92.65M | -$67.30M |
| Interest expense | $51.06M | $21.61M | $40.64M | $17.82M | $6.49M | $73.0K | $3.0K | $39.0K | $0 | $7.10M |
| Pre-tax income | -$68.02M | -$36.76M | -$116.46M | -$98.60M | -$96.75M | -$53.58M | -$115.21M | -$88.33M | -$103.68M | -$67.25M |
| Income tax | -$423.0K | $0 | $371.0K | $87.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$67.59M | -$36.76M | -$101.06M | -$106.14M | -$114.20M | -$81.07M | -$102.09M | -$78.69M | -$99.37M | -$67.25M |
| EPS, basic | -$0.67 | -$0.41 | -$1.77 | -$2.33 | -$2.55 | -$1.91 | -$2.41 | -$1.93 | -$2.78 | -$1.91 |
| EPS, diluted | -$0.67 | -$0.41 | -$1.77 | -$2.33 | -$2.55 | -$1.91 | -$2.41 | -$1.93 | -$2.78 | -$1.91 |
| Diluted shares | 100.3M | 90.6M | 57.0M | 45.5M | 44.8M | 42.5M | 42.4M | 40.8M | 35.7M | 35.3M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $61.53M | $143.25M | $136.71M | $93.22M | $185.64M | $241.15M | $340.52M | $451.50M | $256.38M | $254.57M |
| Short-term investments | $200.0K | - | - | - | - | - | - | - | $39.70M | - |
| Inventory | - | - | - | $0 | $0 | $1.60M | $2.90M | $275.0K | $250.0K | $118.0K |
| Current assets | - | - | - | $122.04M | $225.43M | $315.36M | $391.52M | $487.64M | $323.22M | $312.50M |
| Total assets | $324.72M | $383.54M | $334.27M | $261.22M | $382.08M | $469.47M | $467.47M | $500.84M | $332.88M | $331.43M |
| Current liabilities | $145.75M | $166.27M | $155.14M | $48.13M | $49.35M | $52.02M | $62.60M | $46.87M | $45.45M | $56.17M |
| Total liabilities | $248.82M | $252.51M | $249.57M | $135.28M | $145.60M | $160.63M | $112.00M | $50.57M | $48.90M | $58.45M |
| Shareholders' equity | $75.90M | $131.03M | $84.69M | $125.94M | $236.47M | $308.85M | $355.47M | $450.27M | $283.99M | $272.98M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39.40M | $22.99M | -$24.75M | -$87.44M | -$104.56M | -$80.26M | -$69.14M | -$68.14M | -$52.33M | -$32.71M |
| Capital expenditures | $2.36M | $2.58M | $1.07M | $2.43M | $18.54M | $44.08M | $12.91M | $4.71M | $2.38M | $13.70M |
| Free cash flow | -$41.76M | $20.41M | -$25.82M | -$89.88M | -$123.11M | -$124.34M | -$82.06M | -$72.85M | -$54.71M | -$46.41M |
| Investing cash flow | -$29.48M | -$102.81M | -$15.51M | -$2.76M | $7.28M | -$54.34M | -$35.87M | $35.62M | $1.78M | -$53.14M |
| Financing cash flow | -$16.76M | $89.11M | $82.86M | $1.15M | $47.52M | $27.32M | -$3.86M | $236.49M | $41.27M | $485.0K |
| Stock-based compensation | $6.11M | $3.17M | $5.23M | $6.04M | $11.49M | $10.03M | $26.88M | $37.22M | $50.42M | $58.62M |
| Depreciation and amortization | $20.06M | $19.85M | $18.52M | $18.43M | $14.16M | $7.83M | $6.88M | $2.38M | $3.37M | $2.21M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 61.7% | 435.4% | -64.3% | -33.3% | -35.2% | 159.1% | 7.3% | -36.4% | -40.3% | -9.8% |
| Gross margin | 100.0% | 100.0% | 92.0% | 93.1% | 95.2% | 96.7% | 50.4% | 87.2% | 92.2% | - |
| Operating margin | -41.6% | -121.0% | -1058.4% | -348.6% | -268.1% | -71.0% | -537.4% | -490.3% | -274.8% | -119.2% |
| Net margin | -84.9% | -74.7% | -1099.3% | -412.6% | -295.9% | -136.1% | -444.1% | -367.2% | -294.7% | -119.2% |
| Free cash flow margin | -52.5% | 41.5% | -280.9% | -349.4% | -318.9% | -208.7% | -356.9% | -339.9% | -162.3% | -82.2% |
| Return on equity | -89.1% | -28.1% | -119.3% | -84.3% | -48.3% | -26.3% | -28.7% | -17.5% | -35.0% | -24.6% |
| Return on assets | -20.8% | -9.6% | -30.2% | -40.6% | -29.9% | -17.3% | -21.8% | -15.7% | -29.9% | -20.3% |
| Current ratio | - | - | - | 2.54 | 4.57 | 6.06 | 6.25 | 10.40 | 7.11 | 5.56 |
| Line item | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
|---|---|---|---|---|
| Revenue | $1.99M | $1.64M | $2.00M | $3.56M |
| Operating income | -$29.58M | - | - | - |
| Interest expense | $17.56M | $1.62M | $16.28M | $5.18M |
| Income tax | $6.0K | $107.0K | $258.0K | $0 |
| Net income | -$41.80M | -$17.48M | -$11.37M | -$30.41M |
| EPS, basic | - | - | -$0.20 | - |
| EPS, diluted | - | - | -$0.20 | - |
| Line item | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
|---|---|---|---|---|
| Cash and equivalents | $136.71M | - | - | - |
| Total assets | $334.27M | $209.70M | $227.67M | - |
| Current liabilities | $155.14M | $43.95M | $42.05M | - |
| Total liabilities | $249.57M | $133.58M | $131.12M | - |
| Shareholders' equity | $84.69M | $76.12M | $96.56M | - |
Source: XBRL data Cellectis S.A. files with the SEC, latest filing dated Mar 20, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CLLS | $79.59M | +61.7% | -$67.59M | -84.9% | $112.6M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |